IQVIA (IQV) Financials: Revenue & Earnings

IQV$271.83+6.95 +2.62%

$44.80B

Market Cap

32.14

P/E

19.73

Forward P/E

45

Score

AI Analysis

Snapshot

IQVIA Holdings is a mixed profile at 45/100 — Value 39, Growth 58, Quality 37. Under the hood: P/E 31.7, about 43% below its own multi-year median, plus revenue compounding ~4% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

39
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

58
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

37
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

IQVIA Holdings Inc. (IQV) last printed $271.83. Equity value is $44.80B. Trailing earnings multiple 32.14. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$6.82B$9.7B$10.41B$11.09B$11.36B$13.87B$14.41B$14.98B$15.4B$16.31B

About

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

IQVIA (IQV) Financials: Revenue & Earnings

IQV price $271.83 +6.95 +2.62%

Ticker
IQV
Price
$271.83
Change
+6.95 +2.62%
Market cap ?
$44.80B
P/E ?
32.14
Forward P/E ?
19.73
Dividend yield ?
0.00%
Beta ?
1.16
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Stocklytics score
45
Value
39
Quality
37
Growth
58

Stocklytics score rationale: value 39, quality 37, growth 58.

AI Score 70. IQVIA Holdings Inc. has a market cap of $44.06 billion and a price of $267.33, with a price-to-earnings ratio of 32.1, indicating a premium valuation

Insights · Forecast · Financials · Learn

Stocklytics home · Screener